NovoCure GC awarded 17,755 company shares

NovoCure Ltd reported an insider equity award for its General Counsel, Ben Arye Barak.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

NovoCure Ltd reported an insider equity award for its General Counsel, Ben Arye Barak. He acquired 17,755 ordinary shares on February 28, 2026 at a stated price of $0.00 per share, described as the vesting of performance-based restricted stock units.

Following this grant/vesting, Barak’s direct holdings increased to 192,328 ordinary shares. This transaction reflects stock-based compensation rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 17,755 shares

Grant/Award 1 txn

Insider Ben Arye Barak

Role General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	17,755	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 192,328 shares (Direct)

Footnotes (1)

F1. Represents vesting of performance-based restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NovoCure (NVCR) report for Ben Arye Barak?

NovoCure reported that General Counsel Ben Arye Barak acquired 17,755 ordinary shares through a grant/vesting event. The Form 4 describes this as vesting of performance-based restricted stock units, increasing his direct ownership stake in the company’s ordinary shares.

How many NovoCure (NVCR) shares does Ben Arye Barak own after this Form 4?

After the reported transaction, Ben Arye Barak directly owns 192,328 NovoCure ordinary shares. This total reflects the addition of 17,755 shares acquired through vesting of performance-based restricted stock units reported in the latest Form 4 filing.

Was the NovoCure (NVCR) insider transaction an open-market buy or sale?

The transaction was not an open-market buy or sale. It was coded as a grant or award acquisition, with 17,755 ordinary shares received at a stated price of $0.00 per share from vesting performance-based restricted stock units.

What does the footnote say about the NovoCure (NVCR) Form 4 transaction?

The footnote explains that the 17,755 ordinary shares represent vesting of performance-based restricted stock units. This clarifies that the General Counsel’s additional shares came from equity-based compensation rather than purchases on the open market or other cash transactions.

What is the transaction code used in this NovoCure (NVCR) Form 4?

The transaction uses code “A,” indicating a grant, award, or other acquisition. In this case, 17,755 ordinary shares were acquired at a stated price of $0.00 per share due to vesting of performance-based restricted stock units, increasing the insider’s holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/03/2026 - 04:09 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ben Arye Barak

(Last)

(First)

(Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE

19087

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
02/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares⁽¹⁾	02/28/2026		A		17,755	A	$0.00	192,328	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents vesting of performance-based restricted stock units.

Remarks:

	Steven Robbins, as attorney in fact for Ben Arye, Barak	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR